prolgolimab   Click here for help

GtoPdb Ligand ID: 12991

Synonyms: BCD-100 | BCD100
Immunopharmacology Ligand
Compound class: Antibody
Comment: Prolgolimab (BCD-100) is a chimeric IgG1 anti-programmed cell death 1 (PD-1) monoclonal antibody [1]. It acts as an inhibitor of the PD-1/PD-L1-PD-L2 inhibitory immune checkpoint. The design of prolgolimab abolishes FcγR binding and therefore Fc-mediated effector functions (antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Ekimova VM, Korzhavin DV, Chernykh YS, Nemankin TA, Solovyev VV, Vladamirova Ak, Bulankina IA, Diduk SV, Ustigov IL, Artiukhova MV et al.. (2021)
Anti-PD-1 antibodies, method for producing same and method for using same.
Patent number: US11136408B2. Assignee: Closed Joint-Stock Co "biocad", Biocad JSC. Priority date: 04/07/2017. Publication date: 05/10/2021.
2. Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M et al.. (2021)
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Eur J Cancer, 149: 222-232. [PMID:33872982]